Pharmacological and surgical therapy for the central giant cell granuloma: A long-term retrospective cohort study

详细信息    查看全文

• 作者：Willem Hans Schreuder^a ; ^{w.h.schreuder@amc.uva.nl} ; Henk van den Berg^b ; ^{h.vandenberg@amc.uva.nl} ; Anne Marie Westermann^c ; ^{a.m.westermann@amc.uva.nl} ; Zachary Scott Peacock^d ; ^{zpeacock@partners.org} ; Jan de Lange^a ; ^{j.delange@amc.uva.nl}
• 关键词：Central giant cell granuloma ; Interferon ; Calcitonin ; Maxilla ; Mandible ; Benign bone lesion
• 刊名：Journal of Cranio-Maxillofacial Surgery
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：45
• 期：2
• 页码：232-243
• 全文大小：917 K
• 卷排序：45

文摘

This is a retrospective cohort study of patients with a central giant cell granuloma (CGCG) treated at a single center to assess and compare the different surgical and non-surgical approaches.Material and methodsA cohort with a single histologically proven non-syndrome-related CGCG was selected and reviewed. Patients were allocated to group I (surgery), group II (pharmacotherapy), and group III (pharmacotherapy and surgery). The primary outcome was long-term radiologic response using computed tomography. Secondary outcomes were intermediate radiologic responses and occurrence and severity of side effects.ResultsThirty-three subjects were included in the study. The surgical group (n = 4) included 1 patient with progression during follow-up and a relatively high post-surgical morbidity. Twenty-nine patients started on various pharmacological treatment regimens (groups II and III). Fourteen patients could be managed without additional surgery. One of these lesions showed progression during follow-up. The other 15 lesions underwent additional surgery, and none showed progression during follow-up. Interferon treatment was associated with the most side effects.ConclusionPharmacological agents have a role in the treatment of aggressive and non-aggressive CGCGs by limiting the renewed progression during long-term follow up and the extent and morbidity of surgical treatment.